REGENERON PHARMACEUTICALS, INC. — 13F Holdings & Portfolio
CIK 872589 · latest 13F-HR filed 2026-08-07
REGENERON PHARMACEUTICALS, INC. manages $177.2M in 13F-reported U.S. long-equity assets across 3 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PBLS (64.35%), NTLA (35.35%), ACET (0.30%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 2 new positions, exited 1, added to 1, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
TARRYTOWN, NY 10591
$177.2M
Long-equity book
3
Distinct positions
2026-06-30
Filed 2026-08-07
+2 / −1 / ↑1 / ↓0
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-07 | $177.2M | 3 | 0001104659-26-092709 |
| 2026-03-31 | 2026-05-08 | $47.9M | 2 | 0001104659-26-057922 |
| 2025-12-31 | 2026-02-06 | $33.8M | 2 | 0001104659-26-011601 |